
Roche’s Top-Selling Drug’s New High-Dose Version Fails in Study
(Bloomberg) -- Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the original in a large study, potentially reducing the drugmaker’s ability to fend off cheaper copies. Doubling or …